MedTrace Logo

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL

Last updated 2009-10-15

No results posted yet for this study

Summary

OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies.

II. Determine relevant outcomes of this treatment in these patients including quality of survival, extent of morbidity and mortality from complications of the treatment (e.g., graft versus host disease, regimen related toxicities, B- cell lymphoproliferative disease), and completeness of functional immunoreconstitution.

Conditions

  • Immunologic Deficiency Syndromes
  • Chediak-Higashi Syndrome
  • Common Variable Immunodeficiency
  • Graft Versus Host Disease
  • X-Linked Lymphoproliferative Syndrome
  • Familial Erythrophagocytic Lymphohistiocytosis
  • Hemophagocytic Lymphohistiocytosis
  • X-linked Agammaglobulinemia
  • Wiskott-Aldrich Syndrome
  • Chronic Granulomatous Disease
  • X-linked Hyper IgM Syndrome
  • Severe Combined Immunodeficiency
  • Leukocyte Adhesion Deficiency Syndrome
  • Virus-Associated Hemophagocytic Syndrome

Interventions

DRUG

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

etoposide

DRUG

methotrexate

DRUG

methylprednisolone

DRUG

prednisone

PROCEDURE

Allogeneic Bone Marrow Transplantation

Sponsors & Collaborators

  • Fairview University Medical Center

    lead OTHER

Principal Investigators

  • K. Scott Baker · Fairview University Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-03-31
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006054 on ClinicalTrials.gov